Search Results - antibacterial

29 Results Sort By:
Structurally and Functionally Diverse Heterocyclic Dipeptide Isosteres and Their Derivatives as Antimicrobial Agents and Peptidomimetic Building Blocks
This technology enables rapid, modular synthesis of diverse heterocyclic dipeptide isosteres with potent antimicrobial activity, which can be easily incorporated into peptides to create stable, bioactive molecules for drug discovery and therapeutic applications. Background: The field of antimicrobial drug discovery and peptidomimetic development...
Published: 5/5/2026   |   Updated: 5/4/2026   |   Inventor(s): Sujit Suwal, Olga Novikova
Keywords(s): antibacterial, Bioactive heterocyclic amino esters and peptidomimetics, Chemo-selective synthesis of heterocyclic amino esters, iterative Buchwald Hartwig amination and Suzuki coupling, Technologies
Category(s): Campus > Buffalo State College, Technology Classifications > Drug Design and Synthesis
Novel Antibiotic Inhibiting Elongation Factor Complex in Gram-Positive Bacteria
​ Invention Summary: Antibiotic resistance remains a global health challenge with millions of related deaths each year. Gram-positive bacterial infections, like those caused by Staphylococcus aureus, are likely to acquire and develop resistance to clinically available antibiotics. Therefore, it is crucial to identify and develop novel antibiotics...
Published: 4/15/2026   |   Updated: 6/5/2025   |   Inventor(s): Wlodek Mandecki, Emanuel Goldman, Maxim Chudaev, Mark Henderson, Juan Marugan, Wenjuan Ye, Kenneth Wilson, Dane Parker
Keywords(s): Antibacterial, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
Treatments for tuberculosis and non-tuberculous mycobacterial infections: dual-targeted rifamycin-AAP conjugates (RifaAAPs)
collapse; } ​ Invention Summary: RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains. Researchers indicate that...
Published: 2/20/2026   |   Updated: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
ANTIBACTERIAL AGENTS: DUAL-TARGETED RNA POLYMERASE INHIBITORS (BENZOXAZINO-RIFAAAPS
​ Invention Summary: RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains. Researchers indicate that RifaAAPs comprise...
Published: 2/20/2026   |   Updated: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Infectious Disease, Technology Classifications > Healthcare & Life Sciences
ANTIBACTERIAL AGENTS: CO-SOLVENT-FREE, SURFACTANT-FREE FORMULATIONS OF PYRONINS
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 2/20/2026   |   Updated: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
ANTIBACTERIAL AGENTS: O-ALKYL-DEUTERATED PYRONINS (PYS) AND ARYL PYRONINS (APYS)
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 2/20/2026   |   Updated: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Treatments for drug-susceptible and drug-resistant bacterial infections: arylmyxopyronins (APYs)
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 2/20/2026   |   Updated: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease
Enterovirus D68 capsid inhibitors as antivirals
​ Plaque assay results of Jun11-46-1 and Jun11-54-1 against EV-D68 US/MO/14-18947. Invention Summary: Enterovirus D68 (EV-D68) is an RNA virus that mainly affects children and results in moderate to severe respiratory illness, with the most extreme cases resulting in muscle weakness, paralysis, and death. Currently, there are no antivirals...
Published: 2/20/2026   |   Updated: 1/27/2025   |   Inventor(s): Jun Wang, Yanmei Hu, Kan Li
Keywords(s): Antibacterial, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
Application of a PS-Targeting Molecule Combined with Memory T cell Antigen for Therapeutic, Diagnostic, and Adjuvant Use
​ PS binding molecules could restore inactive or memory T cell functions. Invention Summary: Phosphatidylserine (PS) exposure on the cell surface is often a signal for phagocytosis and can lead to an immunosuppressive effect. Therefore, its inhibition by PS-binding biomolecules can promote a more immuno-responsive microenvironment. However,...
Published: 2/20/2026   |   Updated: 1/21/2025   |   Inventor(s): Alok Choudhary
Keywords(s): Antibacterial, Drug Discovery/Screening
Category(s): Technology Classifications > Cancer, Technology Classifications > Infectious Disease, Technology Classifications > Healthcare & Life Sciences
Nisin-Based Formulations for Oral and Systemic Conditions (UCLA Case Nos. 2023-133 and 2022-306)
UCLA researchers in the Department of Dentistry have found a novel use for nisin alone, and in formulations, for use in the treatment of Alzheimer’s disease, and multiple inflammation states such as brain inflammation, joint inflammation, oral inflammation, systemic inflammation, inflammatory bowel diseases, and non-alcoholic fatty liver disease...
Published: 7/17/2025   |   Updated: 9/19/2024   |   Inventor(s): Yvonne Kapila
Keywords(s): Alzheimers disease, Antibacterial, gut inflammation, Inflammation, microbiome, nanoparticle delivery system, Nanoparticles, nisin, oral inflammation, periodontal disease, periodontal inflammation, periodontal regeneration
Category(s): Therapeutics > CNS and Neurology
1 2 3